<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724711</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-164-0216</org_study_id>
    <nct_id>NCT00724711</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Switching From Epzicom to Truvada</brief_title>
  <acronym>SWIFT</acronym>
  <official_title>A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a prospective, randomized, open-label, multicenter study to evaluate
      the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed
      dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed,
      human immunodeficiency virus type 1 (HIV-1) infected subjects maintained on a
      ritonavir-boosted protease inhibitor (PI/r)-containing antiretroviral (ARV) regimen. Duration
      of treatment is 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a prospective, randomized, open-label, multicenter study to evaluate
      the safety and efficacy of switching from fixed dose ABC/3TC to fixed dose FTC/TDF in
      virologically suppressed, HIV-1 infected subjects maintained on a PI/r-containing ARV
      regimen.

      Subjects were stratified based on the PI/r (ie, lopinavir/ritonavir [LPV/r] versus other
      boosted PIs) in their regimen, and the presence versus absence of comorbidities at screening
      (diabetes mellitus or cardiovascular disease such as hypertension, coronary artery disease,
      hyperlipidemia, history of myocardial infarction, cardiomyopathy, valvular heart disease,
      congenital heart disease, stroke, peripheral vascular disease, or arrhythmias). Subjects were
      randomized 1:1 to switch to FTC/TDF+PI/r or to continue on their existing regimen.

      Subjects received study treatment for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) &lt; 200 Copies/mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL based on TLOVR algorithm at Week 48 was summarized. Participants were considered nonresponders in the TLOVR analysis if they experienced virologic rebound prior to or at Week 48, discontinued study before Week 48, or added a new antiretroviral (ARV) agent prior to completion of the study. Virologic rebound was defined as 2 consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/mL Through Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 200 copies/mL at Week 48 was summarized. Pure virologic response was the percentage of subjects who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/mL Through Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. Pure virologic response was the proportion of participants who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 50 copies/mL or the last HIV-1 RNA value &gt;= 50 copies/mL followed by discontinuation from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 200 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL at Week 48 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Fasting Glucose at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Fasting Lipid Parameters at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Ratio of Fasting Total Cholesterol Over High-density Lipoprotein (HDL) Cholesterol at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline C-Reactive Protein at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Fibrinogen at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha) at Week 48</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Change = Week 48 value minus baseline value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>FTC/TDF (Truvada [TVD]) + PI/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABC/3TC + PI/r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)</intervention_name>
    <description>FTC 200 mg/TDF 300 mg tablet, once a day</description>
    <arm_group_label>FTC/TDF (Truvada [TVD]) + PI/r</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abacavir (ABC)/lamivudine (3TC)</intervention_name>
    <description>ABC 600 mg/3TC 300 mg tablet, once a day</description>
    <arm_group_label>ABC/3TC + PI/r</arm_group_label>
    <other_name>Epzicom, Kivexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (greater than or equal to 18 years) males or non-pregnant, non-lactating females

          -  HIV-1 infected subjects currently receiving a ritonavir-boosted protease inhibitor and
             fixed-dose ABC/3TC regimen continuously for greater than or equal to 3 months

          -  HIV infection as documented by a validated HIV antibody enzyme-linked immunosorbent
             assay (ELISA) and confirmed by one of the following:

               -  Immunoblot detection of HIV antibody

               -  Positive HIV-1 blood culture

               -  Positive HIV-1 serum P24 antigen

               -  HIV-1 plasma viremia greater than 1000 copies/mL by polymerase chain reaction
                  (PCR) or branched-chain deoxyribonucleic acid (bDNA) method

               -  Detection of proviral DNA by PCR

        (If confirmation of HIV infection is not available then repeat testing of HIV antibody will
        be required)

          -  Two consecutive plasma HIV-1 RNA concentration less than 200 copies/mL. The two HIV-1
             RNA determinations ensure that the subject has been virologically-suppressed for at
             least 3 months prior to study entry:

               -  The subject must have a plasma HIV-1 RNA level less than 200 copies/mL using the
                  AmpliPrep/Taqman HIV-1 Test or Roche Amplicor HIV-1 Monitor Test Version 1.5
                  Ultrasensitive method at least 3 months prior to the screening visit, as the
                  &quot;qualifying HIV-1 RNA.&quot;

               -  HIV-1 RNA less than 200 copies/mL measured by bDNA (Chiron 3.0) may be used as a
                  qualifying HIV-1 RNA for entry to the study but not for the confirmatory HIV-1
                  RNA.

               -  The subject must have a confirmed second plasma HIV-1 RNA less than 200 copies/mL
                  at screening, as the &quot;confirmatory HIV-1 RNA.&quot;

               -  The subject must not have a plasma HIV-1 RNA greater than or equal to 200
                  copies/mL between the qualifying and confirmatory HIV-1 RNA measurements.

          -  Subjects receiving lipid-lowering agents (LLA) will be allowed; however, LLAs must be
             stable for greater than or equal to 3 months prior to study entry.

          -  Adequate renal function defined as a calculated CLcr greater than or equal to 50
             mL/min according to the Cockcroft-Gault formula

          -  Negative serum pregnancy test (females of childbearing potential only)

          -  Hepatic transaminases alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) less than or equal to 5 X upper limit of normal

          -  Males and females (of childbearing potential, ie, a non-menopausal female or a female
             with menopause &lt; 2 years, and who has not had a hysterectomy, bilateral oophorectomy,
             or medically documented ovarian failure; this definition includes a young woman who
             has not yet started menstruating), and must agree to avoid pregnancy by sexual
             abstinence, or utilization of a highly effective method of birth control throughout
             the study period and for 30 days following discontinuation of study drug

          -  The ability to understand and sign a written informed consent form, which must be
             obtained prior to initiation of any study procedures

        Exclusion Criteria:

          -  Subjects receiving ABC/3TC and a PI without ritonavir

          -  Subjects receiving other ARV agents (eg, 2 protease inhibitors boosted with low-dose
             ritonavir (ie, &quot;double-boosted PI regimens&quot;), nonnucleoside reverse transcriptase
             inhibitors [NNRTIs], integrase inhibitors, TDF, or other nucleoside reverse
             transcriptase inhibitor [NRTIs]) in addition to ABC/3TC and a ritonavir-boosted
             protease inhibitor

          -  Have known resistance to any of the study agents at any time in the past including
             NRTI resistance mutations (including but not limited to K65R, L74V/I, M184V/I, or
             thymidine analog mutations) and/or PI resistance mutations

          -  A new acquired immunodeficiency syndrome (AIDS) defining condition diagnosed (with the
             exception of CD4 criteria) within 30 days of baseline

          -  Previous therapy with agents with systemic myelosuppressive, pancreatoxic, hepatotoxic
             or cytotoxic potential within 3 months of study start or the expected need for such
             therapy at the time of enrollment

          -  Proven or suspected acute hepatitis in the 30 days prior to study entry

          -  Anticipated need to initiate drugs during the study that are contraindicated with
             protease inhibitors (except upon approval by Gilead)

          -  Receiving ongoing therapy with any of the following (administration of any of the
             following medications must be discontinued at least 30 days prior to the Baseline
             visit and for the duration of the study period):

               -  Nephrotoxic agents (aminoglycoside antibiotics, amphotericin B, cidofovir,
                  cisplatin, foscarnet, intravenous pentamidine, other agents with significant
                  nephrotoxic potential)

               -  Adefovir dipivoxil

               -  Probenecid

               -  Systemic chemotherapeutic agents (ie, cancer treatment medications)

               -  Systemic corticosteroids

               -  Interleukin-2 (IL-2)

               -  Investigational agents (except upon approval by Gilead)

          -  Pregnant or lactating subjects

          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting
             which may confer an inability to receive an orally administered medication

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with subject adherence

          -  Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.
             Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received
             any systemic therapy for KS within 30 days of baseline and are not anticipated to
             require systemic therapy during the study.

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antimicrobial therapy within 15 days prior to screening

          -  Prior history of significant renal or bone disease

          -  Any other clinical condition or prior therapy that, in the opinion of the
             investigator, would make the subject unsuitable for the study or unable to comply with
             the dosing requirements

          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Fralich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health For Life Clinic, PLLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vista Medical Partners</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHF</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Oaks Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Special Immunology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Living Hope Clinical Foundation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Goodman Special Care Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter J. Ruane, MD, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthony M Mills, MD</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Coast Medical Group</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarzana Treatment Center</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alameda County Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Management Institute, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolis Medical</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blick Medical Associates</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Way Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Centers</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary Richmond, MD, PA, Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biogenomx Research Institute, LLC</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Clinical Research</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wohlfeiler, Piperato and Associates, LLC</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Infectious Diseases and Tropical Medicine Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health of South Florida Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Associates of NW FL</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Infectious Diseases</name>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry M. Rodwick, M.D.</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Infectious Disease Group, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Solutions</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Healthcare of Atlanta PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthStar Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Brexton Health Services</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroWest Medical Center</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England - WEST</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University, College of Osteopathic Medicine</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital Internal Medicine Clinic - Mack Office Building</name>
      <address>
        <city>Grosse Point Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Associates, PA</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Infectious Diseases Associates</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>23309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greiger Clinic</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ricky K. Hsu, MD, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Health Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Consultants, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University The Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System Care Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Inf. Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley AIDS Counsel</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon E. Crofoot, MD, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Coulston, MD</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Immunodeficiency Research Collaborative Incorporated</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4J 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CascAids Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4T 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Du Quartier Latin</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion Cientifica del Sur</name>
      <address>
        <city>Ponce</city>
        <zip>00732</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico Inc</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.truvada.com</url>
    <description>Click here for more information about Truvada</description>
  </link>
  <link>
    <url>http://www.gilead.com</url>
    <description>Gilead Website</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2012</results_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at a total of 76 study sites; 70 in the US, 3 in Canada, and 3 in Puerto Rico. The first participant was screened on 15 August 2008, and the last participant was randomized on 27 April 2010. Last participant observation (LPO) date was 19 April 2011</recruitment_details>
      <pre_assignment_details>A total of 393 subjects were screened for entry into this study, and 312 subjects were randomized (156 to each treatment group). One participant randomized to the TVD+PI/r group was never treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FTC/TDF (Truvada [TVD]) + PI/r (Ritonavir-boosted PI Regimen)</title>
          <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
        </group>
        <group group_id="P2">
          <title>Abacavir (ABC) /Lamivudine (3TC) + PI/r (Ritonavir-boosted PI)</title>
          <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TVD + PI/r</title>
          <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
        </group>
        <group group_id="B2">
          <title>ABC/3TC + PI/r</title>
          <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="311"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="9.0"/>
                    <measurement group_id="B2" value="47" spread="9.7"/>
                    <measurement group_id="B3" value="46" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.2" spread="17.40"/>
                    <measurement group_id="B2" value="82.5" spread="15.65"/>
                    <measurement group_id="B3" value="82.3" spread="16.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.8" spread="9.52"/>
                    <measurement group_id="B2" value="174.1" spread="9.55"/>
                    <measurement group_id="B3" value="173.9" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="5.96"/>
                    <measurement group_id="B2" value="27.2" spread="4.93"/>
                    <measurement group_id="B3" value="27.3" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) &lt; 200 Copies/mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL based on TLOVR algorithm at Week 48 was summarized. Participants were considered nonresponders in the TLOVR analysis if they experienced virologic rebound prior to or at Week 48, discontinued study before Week 48, or added a new antiretroviral (ARV) agent prior to completion of the study. Virologic rebound was defined as 2 consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Intent-to-treat (ITT) Analysis Set: Participants who were treated with at least one dose of study drug with no documented resistance to study drug prior to screening.</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) &lt; 200 Copies/mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL based on TLOVR algorithm at Week 48 was summarized. Participants were considered nonresponders in the TLOVR analysis if they experienced virologic rebound prior to or at Week 48, discontinued study before Week 48, or added a new antiretroviral (ARV) agent prior to completion of the study. Virologic rebound was defined as 2 consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
          <population>Intent-to-treat (ITT) Analysis Set: Participants who were treated with at least one dose of study drug with no documented resistance to study drug prior to screening.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The TVD group is at least 12% worse than the ABC/3TC group with respect to the percentage of subjects maintaining HIV-1 RNA &lt; 200 copies/mL through Week 48 (responder rate, as defined by the TLOVR algorithm)
Alternative hypothesis: The TVD group is less than 12% worse than the ABC/3TC group with respect to the percentage of subjects maintaining HIV-1 RNA &lt; 200 copies/mL through Week 48 (responder rate, as defined by the TLOVR algorithm)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This study was designed to show noninferiority (change of &lt; 12%) in regard of proportions of responders (TLOVR) at Week 48.
With 170 subjects in each group, the lower limit of observed one-sided 97.5% confidence interval was expected to be greater than 0.120 with 80% power when the proportion of responders in both treatment groups is 0.820 (82%) at Week 48.
312 subjects were enrolled, representing 8% less than planned (n = 340). As a result, power to claim non-inferiority decreased to 78%.</non_inferiority_desc>
            <param_type>Difference in percentages between groups</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/mL Through Week 48</title>
        <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 200 copies/mL at Week 48 was summarized. Pure virologic response was the percentage of subjects who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>ITT Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/mL Through Week 48</title>
          <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 200 copies/mL at Week 48 was summarized. Pure virologic response was the percentage of subjects who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 200 copies/mL or the last HIV-1 RNA value &gt;= 200 copies/mL followed by discontinuation from the study.</description>
          <population>ITT Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="97.2" lower_limit="92.7" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/mL Through Week 48</title>
        <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. Pure virologic response was the proportion of participants who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 50 copies/mL or the last HIV-1 RNA value &gt;= 50 copies/mL followed by discontinuation from the study.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>ITT Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/mL Through Week 48</title>
          <description>The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. Pure virologic response was the proportion of participants who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values &gt;= 50 copies/mL or the last HIV-1 RNA value &gt;= 50 copies/mL followed by discontinuation from the study.</description>
          <population>ITT Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="87.3" upper_limit="96.2"/>
                    <measurement group_id="O2" value="91.1" lower_limit="85.1" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 200 Copies/mL at Week 48</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL at Week 48 was summarized.</description>
        <time_frame>48 weeks</time_frame>
        <population>ITT analysis set
Missing = Failure: Participants with missing values considered to have HIV-1 RNA levels &gt;= 200 copies/mL
Virologic Success: Last available HIV-1 RNA &lt; 200 copies/mL in the Week 48 window while on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 200 Copies/mL at Week 48</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 200 copies/mL at Week 48 was summarized.</description>
          <population>ITT analysis set
Missing = Failure: Participants with missing values considered to have HIV-1 RNA levels &gt;= 200 copies/mL
Virologic Success: Last available HIV-1 RNA &lt; 200 copies/mL in the Week 48 window while on randomized treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On-Treatment Response Analysis (Missing = Failure)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Snapshot Responder Analysis (Virologic Success)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was summarized.</description>
        <time_frame>48 weeks</time_frame>
        <population>ITT analysis set
TLOVR: No virologic rebound on or before Week 48; no discontinuation before Week 48; no new ARV by study completion
Missing = Failure: Participants with missing values considered to have HIV-1 RNA levels &gt;= 50 copies/mL
Virologic Success: Last available HIV-1 RNA &lt; 50 copies/mL in Week 48 window on randomized treatment</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was summarized.</description>
          <population>ITT analysis set
TLOVR: No virologic rebound on or before Week 48; no discontinuation before Week 48; no new ARV by study completion
Missing = Failure: Participants with missing values considered to have HIV-1 RNA levels &gt;= 50 copies/mL
Virologic Success: Last available HIV-1 RNA &lt; 50 copies/mL in Week 48 window on randomized treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TLOVR Responder Analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                    <measurement group_id="O2" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-Treatment Response Analysis (Missing = Failure)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9"/>
                    <measurement group_id="O2" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Snapshot Responder Analysis (Virologic Success)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9"/>
                    <measurement group_id="O2" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>ITT Analysis Set
Missing = Excluded: Participants with missing values were excluded from this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>ITT Analysis Set
Missing = Excluded: Participants with missing values were excluded from this analysis</population>
          <units>cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="148.3"/>
                    <measurement group_id="O2" value="34" spread="150.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set: The treated analysis set included all randomized participants who received at least one dose of study drug. Participants who were randomized to continue ABC/3TC+PI/r during the study were included in the treated analysis set if they took at least one dose of their study drug after the baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set: The treated analysis set included all randomized participants who received at least one dose of study drug. Participants who were randomized to continue ABC/3TC+PI/r during the study were included in the treated analysis set if they took at least one dose of their study drug after the baseline visit.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="12.18"/>
                    <measurement group_id="O2" value="-4.1" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="14.10"/>
                    <measurement group_id="O2" value="-3.7" spread="15.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Fasting Glucose at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Fasting Glucose at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23.1"/>
                    <measurement group_id="O2" value="1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Fasting Lipid Parameters at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Fasting Lipid Parameters at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21" spread="38.6"/>
                    <measurement group_id="O2" value="-4" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL (low-density lipoprotein)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="33.2"/>
                    <measurement group_id="O2" value="2" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL (high-density lipoprotein)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="10.7"/>
                    <measurement group_id="O2" value="0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51" spread="174.0"/>
                    <measurement group_id="O2" value="-23" spread="178.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Ratio of Fasting Total Cholesterol Over High-density Lipoprotein (HDL) Cholesterol at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Ratio of Fasting Total Cholesterol Over High-density Lipoprotein (HDL) Cholesterol at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.58"/>
                    <measurement group_id="O2" value="-0.1" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline C-Reactive Protein at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set, Subset of Subjects Enrolled after Amendment 3
Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline C-Reactive Protein at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set, Subset of Subjects Enrolled after Amendment 3
Missing = Excluded</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.026" spread="0.4029"/>
                    <measurement group_id="O2" value="0.225" spread="1.2787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Fibrinogen at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set, Subset of Subjects Enrolled after Amendment 3
Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Fibrinogen at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set, Subset of Subjects Enrolled after Amendment 3
Missing = Excluded</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="77.0"/>
                    <measurement group_id="O2" value="14" spread="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha) at Week 48</title>
        <description>Change = Week 48 value minus baseline value</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Treated Analysis Set, Subset of Participants Enrolled after Amendment 3
Missing = Excluded</population>
        <group_list>
          <group group_id="O1">
            <title>TVD + PI/r</title>
            <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
          </group>
          <group group_id="O2">
            <title>ABC/3TC + PI/r</title>
            <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Interleukin-6 (IL-6), Interleukin-10 (IL-10), and Tumor Necrosis Factor-alpha (TNF-alpha) at Week 48</title>
          <description>Change = Week 48 value minus baseline value</description>
          <population>Treated Analysis Set, Subset of Participants Enrolled after Amendment 3
Missing = Excluded</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.69"/>
                    <measurement group_id="O2" value="-0.2" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="4.10"/>
                    <measurement group_id="O2" value="-0.6" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.06"/>
                    <measurement group_id="O2" value="4.7" spread="23.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were reported in the during the randomized, open-label study period between Weeks 0 through 48.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TVD + PI/r</title>
          <description>Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The participant's prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.</description>
        </group>
        <group group_id="E2">
          <title>ABC/3TC + PI/r</title>
          <description>Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Streptococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Shunt Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Burns Third Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hallucination, Auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dara Wambach, MA, Associate Director, Regulatory Affairs</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>650 522 5163</phone>
      <email>Dara.Wambach@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

